Benperidol

Pharmacodynamics

Benperidol is a strong dopamine receptor antagonist (D₂ (K_i 0.027 nM) and D₄ (K_i 0.066 nM))^[7] with weaker serotonin receptor antagonism (5-HT_2A (K_i 3.75 nM)).^[7] In high doses, it has antihistaminergic and alpha-adrenergic^[which?] properties. It possesses minimal anticholinergic properties.^[8]

Although benperidol was developed relatively early in the history of antipsychotic drugs, it exhibits a uniquely high and selective affinity for the human dopamine D₂ receptor when compared with all other human dopamine receptor subtypes. This is evident from its nanomolar binding affinities, which stand out even among both typical and atypical antipsychotics. Benperidol is also considered to possess one of the greatest selectivity ratios for dopamine receptors over 5-HT_2A serotonin receptors, although this distinction is surpassed by certain neuroleptics such as amisulpride and sulpiride.^[10][11] Dopamine receptors play central roles not only in cognition, emotion, and motor control—key domains affected in schizophrenia—but also in various unconscious biological processes. The emphasis on D₂ receptor blockade in antipsychotic drug design stems from its critical role in these functions and its dense expression in brain regions implicated in schizophrenia, such as the striatum and frontal cortex.^[12][13] Benperidol's preferential binding to the D₂ receptor—over other dopamine receptor subtypes such as D₃ and D₄—is also unusually strong, with approximately a twofold greater selectivity. This distinguishes it from antipsychotics like haloperidol and perphenazine, which show more balanced D₂/D₃ binding ratios (e.g., 0.7–0.3 or 0.13),^[14] as well as from cariprazine, which demonstrates an even higher D₃ affinity relative to D₂ (D₂–D₃ ratio of 0.49–0.085).^[15]

Pharmacokinetics

Benperidol is absorbed well and undergoes extensive first pass metabolism. One percent of benperidol is excreted in urine. The half-life of benperidol is 8 hours.^[8]